Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
On Mar. 1, 2023, BioNTech and Pfizer announced that they had submitted an application to the U.S. Food…
-
-
Biotechnology | COVID-19 | Medicine | Vaccine
Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster demonstrating improved immune response against Omicron sublineages
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
-
Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
-
Novavax initiated phase 3 trial of its COVID-19 Omicron strain vaccine as a booster
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
-
Study found ‘natural immunity’ from Omicron weak and limited
On May 18, 2022, researchers at Gladstone Institutes and UC San Francisco (UCSF) reported that unvaccinated people, infection…
-
InteliSwab COVID-19 rapid test validated to detect Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants
On May 17, 2022, OraSure Technologies announced that its InteliSwab COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1,…
-
Roche provided molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern
On Mar. 15, 2022, Roche announced available testing solutions that can identify the SARS-CoV-2 B.1.1.529 variant and differentiate…
-
Pfizer and BioNTech provided update on Omicron variant
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…
